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Abstract—This paper presents results from a scoping study 
undertaken with the intention of demonstrating the applicability 
of reflectance Near-Infrared (NIR) spectroscopy in classification 
of pharmaceutical type based on active ingredient.  The part of 
the process selected for the scoping study is the packaging step in 
the manufacturing of pharmaceuticals.  The rational for the 
selection of the packaging step is in older processing lines the 
product is classified after tablet coating and before blister 
packaging using visual automatic inspection techniques however 
for 100% conformance a more discriminating technique is 
required.  In this study, NIR spectra (with wavelengths between 
400nm and 1100nm) were obtained for samples pertaining to 3 
different types of pharmaceuticals Quetiapine, Ibuprofen and 
Paracetamol. The dimensionality of the data set was reduced 
using Principal Components and the data was feed into a back 
propagation neural network configured to classify the data based 
on active ingredient type. The recognition rates achieved in this 
study were high enough to suggest that NIR spectroscopy is a 
viable method of ensuring 100% identification of pharmaceutical 
type prior to packaging for the pharmaceuticals tested. 
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ingredient.  
 
I. INTRODUCTION 
Quality control is an essential element of pharmaceutical 
production processes because of the high safety levels 
demanded in assuring the pharmaceuticals quality [1] and the 
legal requirements that finished pharmaceuticals conform too 
and the number of different measures and tests that are 
prescribed by various international regulatory regimes [2,3].   
Within most pharmaceutical manufacturing lines the 
quality control tool of automatic inspection prior to packaging 
has become common place [4] and most modern 
pharmaceutical lines use advanced inspection systems 
operating in the visual region of the Electromagnetic Spectrum 
to assess product shape, colour and pressed label identifier [5].  
In general these systems are very good at ensuring the correct 
product is packaged however automatic inspection systems 
using only the visual spectrum are limited by their range of 
wavelengths when tasked with making an inference on the 
tablets chemical composition [6]. 
NIR spectroscopy is defined as compilation and analysis of 
electromagnetic radiation between the wavelengths of 700-
2500nm [7].  The NIR electromagnetic spectrum has the 
capacity to make an inference on a pharmaceutical tablet’s 
chemical composition and provides a rapid analytical 
technique to acquire product information [8]. NIR 
spectroscopy has thus become an important tool in product 
conformance testing and has been widely used in the 
pharmaceutical sector with successful applications having 
been reported [9,10]. 
Implementation of NIR measurement technologies is 
considered a major cost for many pharmaceutical 
manufacturers because new machinery equipped with NIR 
instrumentation is expensive and replacing existing machinery 
with new NIR instrumentation equipped machinery means 
realizing the depreciation of the older machinery.  A risk 
associated with deployment of NIR sensing technology is that 
the NIR spectrometer’s configuration may be unsuitable for 
measurements of the product under investigation due to 
product size, unique nature of the chemical composition, and 
spectral range selected [11].  In respect to these uncertainties it 
is often considered prudent to undertake a pre-deployment 
scoping study first.  In this scoping study the back propagation 
neural network classifier was selected to determine the 
predictive power of NIR instrumentation due to it being a 
general purpose classification tool which is able to model both 
linear and non-linear relationships [12].   
In this scoping study, production tablets at the packaging 
stage had their spectra captured with a low cost spectrometer 
(operating over the range of 400-1100nm) mounted on an 
optical layout table.  The pharmaceutical spectra are 
preprocessed and then a neural network is used to perform a 
classification; finally recognition statistics are computed using 
the classification data.  The recognition statistics are then used 
to make a decision about the potential of NIR spectral analysis 
to recognize pharmaceutical tablet type. 
 
 
II. METHOD AND MATERIALS 
 
A. Manufacture of Pharmaceuticals  
The production process for manufacture of pharmaceutical 
tablets involves several steps  
• In the first step of granulation, a mixture of active 
ingredient, cellulose, and starch is blended and then 
granulated in a fluid bed reactor that is supplied with 
a binder solution and then dried to produce granulate.  
• During the second step, granulate is milled to spread 
the active ingredient homogenously.  
• For the third step, granulate is pressed to produce a 
non-coated tablet.  
• The fourth step requires the tablets are coated with a 
film of lacquer.  
• Lastly the tablets are packaged in a high speed 
packaging line for distribution to human consumers. 
These steps are illustrated in a process flow diagram 
shown in Fig.1 below. 
 
 
 
Fig. 1. Process flow diagram of pharmaceutical manufacturing process. 
 
 
B. Pharmaceutical Formulation 
 
The formulation studied consisted of tablets containing 
100mg, 200mg and 300 mg dosages Quetiapine.  The 
Quetiapine tables had the same concentration of active 
ingredient but were of different sizes to produce different 
dosages.  Two other tablet types, Ibuprofen (500mg) and 
Paracetamol (500mg), were used as samples. 
 
C. Recording of NIR Spectra 
 
The pharmaceutical tablet’s spectrum was captured using a 
Zeiss MMS1 VIS-ENH spectrometer [13].  This spectrometer 
used a fibre optic coupling cable to acquire the signal from the 
tablets.  The spectrometers electronic interface was 
manufactured by Australian Innovative Engineering, 
Queensland [14] and used an Ethernet connection which was 
interfaced with a computer. 
Pharmaceutical tablets samples were placed on a holding 
unit mounted to an optical layout table (see Fig. 2). The 
samples were illuminated with a 100W halogen source that 
was placed 1cm from the sample in the diffuse reflectance 
configuration.   
 
 
 
 
 
                                 
Fig. 2.  Fibre optic coupling input to Zeiss MMS1 spectrometer, sample 
holder (with table located on it) and lighting configured in diffuse 
reflectance mode. 
  
D. Preprocessing of the Spectra 
 
 
The measurements from the spectrometer were taken in 
reflectance mode and the mathematical treatment of the 
spectral variables was  
     xi=log10(1/R),           (1) 
 
where R represents the reflectance spectral intensity at a 
specified wavelength. 
A dark reference spectrum from was captured to remove 
the effects of stray light and a reference spectrum from a 
ceramic tile was used to standardize the signal to changes in 
illumination intensity.   
          xistd=(xi-xd)/xc,           (2) 
 
where xd is the reference dark spectrum and xc is the ceramic 
tile reference spectrum. 
The Standard Normal Variate (SNV) algorithm was 
implemented to reduce the effects of light scatter produced by 
shape and geometric irregularities in the objects under 
observation [15].  The SNV works on individual sample 
spectra by a transformation of the centre of each spectrum and 
then scaling the spectrum by its own standard deviation. 
          xi SNV=(xistd-x�)/Sd,           (3) 
 
where Sd represents the spectrum’s standard deviation.  
 
 
E. Principal Component Dimension Reduction 
 
The principal components transformation is a linear 
geometric transformation that reconfigures the data from a 
high-dimensional space to a space of fewer dimensions [16].  
The principal components algorithm reduces the dimensions 
of the spectral data matrix by forming basis vectors that 
contain information relating to the variation in the spectral 
data matrix.  The basis vectors are in computed as the 
eigenvectors p, of, 
XXT,            (4)  
where X is the m×n matrix of spectral intensity measurements 
containing m observations of n wavelength. In general, the 
higher order components tend to contain noise and the first 
few components contain chemical composition information so 
only the first few a eigenvectors p1,..., pa are retained in the 
principal component dimension reduction.  
 
F. Neural Network Classification 
 
The neural network used for the classification problem was 
a back propagation neural network utilising a Jacobian matrix 
(see Fig. 3).  This neural network consisted of three layers: an 
input layer, an intermediate hidden layer and an output layer 
and is configured in the feed forward direction [16].  A 
number of trials were performed using different numbers of 
nodes within the hidden layer for the purpose identifying a 
structure that would give an acceptable preliminary result in a 
reasonable time without undue stress being placed on the 
computing infrastructure.  From these trials a structure 
containing and input layer that comprised of 5 inputs nodes 
(one input node per selected principal component), one hidden 
layer that comprised of 10 nodes and an output layer that 
comprised of three nodes (one output node for each class of 
tablet) was used for the purpose of reporting the neural 
networks classification performance in trial experiments.  The 
classification information from the output layer was used to 
compute pharmaceutical tablet recognition statistics. 
 
G. Data Analysis 
 
A Hewlet Packard laptop that used two 2.8GHz processors 
running the Windows 7 operating system and SpecAquisition 
 
Fig. 3. Neural network with input layer, hidden layer and output layer. 
V30 software from Australian Innovative Engineering, 
Victoria, [14] was used to capture the data from the 
spectrometer.  The data was then saved and imported into 
Matlab 2011 [18] where the data analysis of standardisation 
SNV pre-processing, principal component dimension 
reduction and neural network classification was undertaken.   
 
III. RESULTS AND DISCUSSION 
 
A. Spectrometer Calibration Results  
 
The spectrometer was calibrated using a mercury argon 
lamp, spectrums were recorded of excited mercury argon gas 
and a plot of spectral intensity vs. wavelength for the 
calibration lamp is shown in Fig. 4.  The theoretical spectral 
resolution of the Zeiss MMS1 instrument is 2.7nm but the 
practical resolution is determined by the optical components 
used and their resulting optical aberrations.  Inspection of two 
prominent spectral peaks located at 696.5nm, 706.7nm 
indicate that a resolution of around 10nm is achievable in 
practice.    
 
B. Analysis of Principal Components 
 
The standardized SNV treated spectra had principal 
component dimension reduction applied and then the 
cumulative variance of the principal components was 
computed.  The cumulative variance statistic revealed that the 
first factor (PC1) contained most of the chemical and physical 
information with 89.3% of the dataset’s variance. 
 
Fig. 4. Plot of spectra from an argon mercury lamp vs. wavelength. 
 
 
Fig. 5. Principal component scatter plots using the first 4 principal components of the pharmaceutical dataset comprising of 21 Ibuprofen spectrums, 20 
Paracetamol spectrums and 61 Quetiapine spectrums.   
Fig. 5 show scatter plots for the first 4 principal 
components of the pharmaceutical spectra and from inspection 
of Fig. 5a, 5b and 5c (PC1 vs. PC2, PC1 vs. PC3 and PC1 vs. 
PC4) a clear trend emerges with Paracetamol samples at 
different positions between the centre and the left hand side of 
the plot, Ibuprofen clustered in the centre and Quetiapine at 
different positions between the centre and the right hand side 
of the plot.  In these plots Quetiapine had the greatest 
geometric spread of values and this has been attributed to the 
Quetiapine samples having a greater variability in geometric 
shape because the Quetiapine samples inspected were of 
different dosage levels.  The remaining plots (Fig 5e, Fig. 5f 
and Fig. 5g) show much more overlap of the samples and this 
further suggests that principal component 1 has the greatest 
discriminatory information 
 
C. Neural Network Training 
 
The neural network was trained using a training set 87 
samples (19 Ibuprofen, 15 Paracetamol and 53 Quetiapine) 
and then an independent set of 15 samples (5 Ibuprofen, 2 
Paracetamol and 8 Quetiapine) was used to access the 
prediction abilities of the classifier.   
The training data set was further broken into two sets, a 
calibration set of 72 samples and a validation set of 15 
samples.  During training at 36 epoches, the Mean Squared 
Error (MSE) of the validation set produced a minima of 
0.0064 before a consistent increase in MSE; indicating 
termination of training (see Fig. 6).  The trained neural 
network was then used to undertake the classification of 
samples in the training set and then the prediction set. 
 
D. Recognition Performance of the Neural Network 
 
In reference to Table I, the first recognition statistic ‘*’ 
refers to the data set of 87 spectra used in training the 
classifier. The recognition statistic is a percentage value of 
tablets correctly classified relative to total number of 
pharmaceutical tablets present for each respective class in the 
training data set.  The second recognition statistic ‘**’ refers 
to an independent set of 15 spectra not used in training the 
classifier. The recognition statistic is a percentage value 
computed from the number of tablets correctly classified 
relative to total number of tablets present for each respective 
class in the independent data set. 
The classification statistics achieved in recognising the 
different tablets with the classifier (see Table I) show that the 
classifier achieved a recognition value of 100% in identifying 
Ibuprofen and Paracetamol and 98.1% for Quetiapine in the 
training set. The reverse error was a recognition value of 
100% in identification of Ibuprofen and Quetiapine in the 
training set. 
TABLE I. Recognition statistics computed using classification data from Pharmaceutical tablet spectra. 
Active ingredient Number in 
calibration 
set 
Number 
correctly 
classified 
* Percentage 
correctly 
classified 
Number in 
prediction 
set 
Number 
correctly 
classified 
** Percentage 
correctly 
classified 
Ibuprofen 19 19 100 2 2 100 
Paracetamol 15 15 100 5 5 100 
Quetiapine 53 52 98.1 8 8 100 
 
 
Fig. 6. Neural Network MSE vs. Epoch iterations 
The inability of the neural network classifier to obtain 
100% recognition of Quetiapine does not necessarily suggest 
that the classifier is inefficient at separation of Quetiapine 
from the other two tablet types tested. The overall prediction 
statistics are excellent however the Quetiapine result indicates 
that the classifier will omit samples of Quetiapine in order to 
obtain a 100% reverse error for Quetiapine.  In a production 
situation if Quetiapine was being packaged and the intention 
of the classifier was to ensure only Quetiapine tablets be 
packaged then this classifier would be considered highly 
efficient however if the secondary aim was to ensure that all 
the Quetiapine be recognised and packaged (to optimize 
production) then this classifier has scope for improvement. 
 
IV. FUTURE WORK 
 
This study indicated that the use of NIR reflectance 
spectroscopy allows fast non-destructive recognition of active 
ingredients in the different products investigated in a 
laboratory environment however in a manufacturing situation 
where the packaging step in the production line handles much 
larger numbers of different product batches over the course of 
a year, a much more substantial calibration would be required 
before it can be concluded that the technique provides 
sufficient recognition of all the different batches that are 
produced.  We will attempt to address this problem in future 
work by increasing the sample size and variety of products 
used in calibrations and test other classification algorithms. 
The current investigations were undertaken using an 
optical layout table within a controlled laboratory 
environment; a commercial manufacturing environment 
contains many more sources of errors such as mechanical 
vibration, temperature fluctuation and potential movement of 
the product during inspection.  Investigations of these error 
sources were outside the scope of this study and accordingly 
our future investigations will attempt to develop calibrations 
that incorporate these sources of errors.  
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